School of Pharmacy Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
J Mol Neurosci. 2018 Feb;64(2):185-199. doi: 10.1007/s12031-017-1008-8. Epub 2017 Dec 16.
Human umbilical cord blood (HUCB) transplantation has become an alternative cell therapy for hematological and oncological malignancies in the clinic and is considered for neurological disorders. The heterogeneity in the content of the different stem and progenitor cells composing HUCB mononuclear cells (MNC) may influence their engraftment and neurotherapeutic effect. We hypothesized that CD45 pan-hematopoietic marker expression is heterogeneous in MNC, and therefore, CD45 subpopulation enrichment for neurotherapy may provide a tool to overcome cellular variance in different HUCB units. We employed an immunomagnetic separation method to isolate and characterize HUCB CD45 pan-hematopoietic subpopulation and to investigate whether the vaginal or cesarean deliveries influence their neurotherapeutic effect in a traumatic brain injury (TBI) mouse model. Adult C57BL/6J male mice were subjected to moderate TBI and intravenously xenotransplanted with 1 × 10 CD45 cells derived from either vaginal or cesarean HUCB units. A large heterogeneity in the expression of CD45 marker in MNC, both in vaginal and cesarean HUCB units, was found, regardless of the number of live births. A higher expression of hematopoietic markers was found in the CD45 subpopulation while low expressional levels of typical mesenchymal markers were detected. Neurotherapeutic effects, evaluated with an established neurological severity score and novel object recognition test, indicated improved functional motor and memory recovery and found independent of delivery type. Cytokine analysis in extracts of TBI brain cortices indicated an acute immunomodulatory effect by HUCB CD45 subpopulation upon xenotransplantation. These results may provide insights to CD45 marker as a predictor of HUCB units' quality for neurotherapy in TBI.
人脐带血(HUCB)移植已成为临床治疗血液系统和肿瘤恶性肿瘤的一种替代细胞疗法,并被认为可用于治疗神经疾病。组成 HUCB 单核细胞(MNC)的不同干细胞和祖细胞的含量存在异质性,这可能会影响它们的植入和神经治疗效果。我们假设 MNC 中的 CD45 泛造血标志物表达存在异质性,因此,CD45 亚群的富集可能为神经治疗提供一种克服不同 HUCB 单位中细胞变异性的工具。我们采用免疫磁珠分离法分离和鉴定 HUCB CD45 泛造血亚群,并研究阴道或剖宫产分娩是否会影响其在创伤性脑损伤(TBI)小鼠模型中的神经治疗效果。成年 C57BL/6J 雄性小鼠接受中度 TBI,并静脉注射源自阴道或剖宫产 HUCB 单位的 1×10 CD45 细胞。无论活产数量如何,均发现 MNC 中 CD45 标志物的表达存在很大的异质性,无论是在阴道还是剖宫产 HUCB 单位中。在 CD45 亚群中发现了更高水平的造血标志物,而检测到典型间充质标志物的表达水平较低。使用既定的神经严重程度评分和新物体识别测试评估神经治疗效果表明,功能运动和记忆恢复得到了改善,且这种改善与分娩方式无关。TBI 大脑皮质提取物中的细胞因子分析表明,HUCB CD45 亚群在异种移植后具有急性免疫调节作用。这些结果可能为 CD45 标志物作为 TBI 神经治疗中 HUCB 单位质量的预测指标提供了新的见解。